Table 4. Clinical characteristics of patients with and without the recurrence of AF.
| Variables | PAF | non-PAF | ||||
|---|---|---|---|---|---|---|
| No Recurrence | AF Recurrence | P Value | No Recurrence | AF Recurrence | P Value | |
| Patients, n (%) | 50 | 23 | 26 | 19 | ||
| Male sex, n (%) | 42(84) | 19(82.6) | 1 | 22(84.6) | 19(100) | 0.13 |
| Age, years (IQR) | 57.0(49.0–62.0) | 59.0(54.5–62.0) | 0.56 | 58.5(53.5–62) | 56.0(48.5–62) | 0.39 |
| BMI, kg/m2 (IQR) | 24.3(22.1–27.9) | 22.3(21.2–24.4) | 0.015* | 23.7(21.4–26.1) | 24.5(21.4–26.1) | 0.68 |
| Duration of AF, months (IQR) | 31.0(10.5–72.0) | 36.0(4.5–60.0) | 0.42 | 15.5(5.3–36.0) | 36.0(20.5–72.0) | 0.008* |
| Hypertension, n (%) | 17(34) | 6(26.1) | 0.594 | 5(19.2) | 9(47.4) | 0.057 |
| Diabetes mellitus, n (%) | 4(8) | 3(13.0) | 0.671 | 1(3.8) | 6(15.8) | 0.295 |
| Stroke, n (%) | 2(4) | 3(13.0) | 0.317 | 2(7.7) | 3(15.8) | 0.636 |
| History of TCM, n (%) | 4(8) | 1(4.3) | 1 | 1(3.8) | 5(15.8) | 0.295 |
| Pre-ablation anti-arrhythmic drugs | ||||||
| Class Ⅰ AAD, n (%) | 26(52) | 11(47.8) | 0.804 | 7(27.0) | 2(10.5) | 0.264 |
| Class Ⅲ AAD, n (%) | 1(2.0) | 0(0.0) | 1 | 1(3.8) | 0(0.0) | 1 |
| βblocker, n (%) | 20(40) | 7(30.4) | 0.602 | 12(46.1) | 11(57.9) | 0.55 |
| ACEI/ARB, n (%) | 15(30) | 3(13.0) | 0.151 | 7(26.9) | 9(47.4) | 0.212 |
| Statin, n (%) | 9(18) | 3(13.0) | 0.74 | 6(23.1) | 8(36.8) | 0.34 |
| LV ejection fraction, % (IQR) | 69.0(65.0–72.0) | 67.0(65.0–70.0) | 0.38 | 63.5(60.0–65.8) | 64.0(54.5–68.0) | 0.94 |
| LVDd mm (IQR) | 50.0(45.3–51.8) | 48.0(46.0–52.5) | 0.97 | 48.0(45.0–50.8) | 48.0(46.5–52.0) | 0.55 |
| Left atrial anteroposterior echocardiographic dimension, mm (IQR) | 40.0(36.0–42.8) | 40.0(36.0–42.5) | 1 | 42(37.3–45.5) | 41(39.5–46.0) | 0.49 |
| NT proBNP, pg/ml (IQR) | 60.5(24.8–146.0) | 70.0(54.8–108.5) | 0.35 | 422(322–671) | 375(190–928) | 0.99 |
Data are n (%), and median (IQR; 25%―75% interquartile range).
* significant difference
AAD, anti-arrhythmic drug; ACEI, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BMI, body mass index; LV, left ventricle; LVDd, left ventricular end-diastolic diameter; non-PAF, non-paroxysmal atrial fibrillation; PAF, paroxysmal atrial fibrillation; TCM, tachycardia-induced cardiomyopathy